Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator

CONCLUSION: In a multicenter cohort of ICD-carriers with SHD, class-IC-AADs were associated with a low rate of pro-arrhythmic effects or cardiovascular mortality. The majority of patients remained free from sustained VA during a follow-up of > 2 years. Further efforts should be made to evaluate the safety of class-IC-AADs in SHD patients receiving contemporary cardiovascular therapy.PMID:38372753 | DOI:10.1007/s00392-024-02394-6

Source: Clin Med Res - February 19, 2024 Category: Research Authors: Maura M Zylla Julian Wolfes Ruben Schleberger Dennis Lawin Meinhard Kieser Florian Reinke Lars Eckardt Andreas Rillig Christoph Stellbrink Dierk Thomas Norbert Frey Patrick Lugenbiel Source Type: research